Business
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
About this update from Hanmi Science Co., Ltd
[{"type":"text","content":"Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments","length":126,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.","length":209,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hanmi Pharmaceutical)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hanmi Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":216,"url":"https://media.zenfs.com/en/prnewswire.com/7824ed3a5da34bc8f0395aa4452f3fe9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aqm8MXwHLw.bwQ6quObq5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7824ed3a5da34bc8f0395aa4452f3fe9","width":400,"height":216}},"href":"https://mma.prnewswire.com/media/2034330/Hanmi_Pharmaceutical_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity therapy, as well as the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.).","length":368,"tagName":"p"},{"type":"text","content":"Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico.","length":197,"tagName":"p"},{"type":"text","content":"Mexico is one of the countries with the highest obesity rates globally, with obesity prevalence reaching 36.86%, while diabetes prevalence stands at 16.4%.[1] As demand in the market extends beyond weight loss and maintenance therapy to include blood glucose management, the agreement reflects confidence in efpeglenatide's global scalability and strategic value.","length":367,"tagName":"p"},{"type":"text","content":"Founded in 1941, Sanfer is Mexico's largest privately held pharmaceutical company. Leveraging its extensive sales and distribution network across Latin America an...